Flu Vaccine Market 2021 Status and Outlook, Industry Growth Rate, Opportunities and Challenges to 2025

Japan, Japan, Wed, 05 Jan 2022 01:26:24 / Comserve Inc. / -- United States flu vaccine market is expected to reach nearly US$ 3 Billion by 2024.

United States flu vaccine market is expected to reach nearly US$ 3 Billion by 2024. Growth in US flu vaccine market can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against flu vaccine and introduction of quadrivalent flu vaccine.

Enquire Before Purchasing This Report:- https://www.sdki.jp/sample-request-53467

Long–term Growth Projection and Development:

• Sanofi to Acquire Protein Sciences Corporation
• It is likely that more than 185 Million persons being vaccinated with flu vaccines in 2024.
• Nearly 160 Million doses of flu vaccines have shipped to US for the 2017-2018 flu season
• It is projected that GSK flu vaccine sales value will reach around US$ 1.5 Billion by 2024
• BiondVax reports positive phase 2b clinical trial results for its universal flu vaccine

"Flu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis, Market Forecast 2017-2024" provides a deep and thorough evaluation of the United States flu vaccine market. The report provides an in–depth analysis of the flu vaccination pattern in both Children and Adults in the United States. It also provides essential insights into flu vaccine production, price, consumption, supply, distribution, demand and specification. It also covers reimbursement pattern and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials and promising flu vaccines in the clinical development. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.

The report concludes with the profiles of major players in the US flu vaccine market such as Sanofi Pasteur, GSK and Seqirus. The major market players are evaluated on various parameters such as company overview, product outlook, latest development & trends and sales analysis of flu vaccine market from 2011 to 2022. The report also entails major drivers and inhibitors in the US flu vaccine market.

Key Topics Covered in the Report

• Market Overview: United States Flu Vaccine Market (2010 - 2024)
• United States Number of Persons Vaccinated with Flu Vaccine (2010 - 2024)
• United States Flu Vaccine Production, Price, Consumption, Supply, Distribution, Demand and Specification
• Reimbursement & Regulatory System in the US Flu Vaccine Market
• Mergers, Acquisitions, Key Agreements & Collaborations
• Promising Flu Vaccine in Clinical Development
• Flu Vaccine Clinical Trial Insights by Phase, Company & Country
• Key Drivers and Inhibitors of the US Flu Vaccine Market
• Key Companies Analysis

Major Flu Vaccines Covered Under This Report Are:


• Fluzone High–Dose
• Fluzone Quadrivalent
• Intradermal (ID) Trivalent
• Vaxigrip
• Fluarix Quadrivalent
• Flulaval Quadrivalent
• Flucelvax Quadrivalent
• Afluria Quadrivalent
• Agrippal
• Fluad
• Fluvirin
• Fluvax

Enquire Before Purchasing This Report:- https://www.sdki.jp/sample-request-53467

Key Companies Covered in This Report:

• Seqirus
• Sanofi Pasteur
• GlaxoSmithKline(GSK)

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.

For more information, please contact:

Shibuya Data Count
Email: sales@sdki.jp
Tel: + 81 3 45720790

The post Flu Vaccine Market 2021 Status and Outlook, Industry Growth Rate, Opportunities and Challenges to 2025 appeared first on Comserveonline.